Literature DB >> 1733445

An investigation of different methods of cell cycle analysis by flow cytometry in rectal cancer.

N Scott1, D Cross, M I Plumb, M F Dixon, P Quirke.   

Abstract

Entities:  

Mesh：

Year:  1992        PMID： 1733445      PMCID： PMC1977355          DOI： 10.1038/bjc.1992.2

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  13 in total

1.  Interinstitutional variability in DNA flow cytometric analysis of tumors. The National Cancer Institute's Flow Cytometry Network Experience.

Authors:  J S Coon; A D Deitch; R W de Vere White; L G Koss; M R Melamed; J E Reeder; R S Weinstein; R P Wersto; L L Wheeless
Journal:  Cancer       Date:  1988-01-01       Impact factor: 6.860

2.  Nucleic acid flow cytometry in large cell lymphoma.

Authors:  P McLaughlin; B M Osborne; D Johnston; P Jennings; J J Butler; F Cabanillas; B Barlogie
Journal:  Cancer Res       Date:  1988-11-15       Impact factor: 12.701

3.  Check samples for laboratory self-assessment in DNA flow cytometry. The National Cancer Institute's Flow Cytometry Network experience.

Authors:  J S Coon; A D Deitch; R W de Vere White; L G Koss; M R Melamed; J E Reeder; R S Weinstein; R P Wersto; L L Wheeless
Journal:  Cancer       Date:  1989-04-15       Impact factor: 6.860

4.  Prognostic implications of ploidy and proliferative activity in diffuse large cell lymphomas.

Authors:  K D Bauer; D E Merkel; J N Winter; R J Marder; W W Hauck; C B Wallemark; T J Williams; D Variakojis
Journal:  Cancer Res       Date:  1986-06       Impact factor: 12.701

5.  Association of DNA content and proliferative activity with clinical outcome in patients with diffuse mixed cell and large cell non-Hodgkin's lymphoma.

Authors:  T N Wooldridge; H L Grierson; D D Weisenburger; J O Armitage; W G Sanger; M M Collins; J L Pierson; M E Pauza; R Fordyce; D T Purtilo
Journal:  Cancer Res       Date:  1988-11-15       Impact factor: 12.701

6.  Clinical importance of DNA content in rectal cancer measured by flow cytometry.

Authors:  J R Jass; K Mukawa; H S Goh; S B Love; D Capellaro
Journal:  J Clin Pathol       Date:  1989-03       Impact factor: 3.411

7.  The influence of tumour cell DNA abnormalities on survival in colorectal cancer.

Authors:  N C Armitage; R A Robins; D F Evans; D R Turner; R W Baldwin; J D Hardcastle
Journal:  Br J Surg       Date:  1985-10       Impact factor: 6.939

8.  Retrospective analysis of the prognostic significance of DNA content and proliferative activity in large bowel carcinoma.

Authors:  B Schutte; M M Reynders; T Wiggers; J W Arends; L Volovics; F T Bosman; G H Blijham
Journal:  Cancer Res       Date:  1987-10-15       Impact factor: 12.701

9.  Prognostic significance of DNA aneuploidy and cell proliferation in rectal adenocarcinomas.

Authors:  P Quirke; M F Dixon; A D Clayden; P Durdey; J E Dyson; N S Williams; C C Bird
Journal:  J Pathol       Date:  1987-04       Impact factor: 7.996

10.  DNA content in high and intermediate grade non-Hodgkin's lymphoma-prognostic significance and clinicopathological correlations.

Authors:  R A Cowan; M Harris; M Jones; D Crowther
Journal:  Br J Cancer       Date:  1989-12       Impact factor: 7.640
View more
  4 in total

1.  Which proliferation markers for routine immunohistology? A comparison of five antibodies.

Authors:  D S Rose; P H Maddox; D C Brown
Journal:  J Clin Pathol       Date:  1994-11       Impact factor: 3.411

Review 2.  Management of carcinomas of the upper gastrointestinal tract.

Authors:  P Ellis; D Cunningham
Journal:  BMJ       Date:  1994-03-26

3.  DNA ploidy and proliferative activity (S-phase) in childhood soft-tissue sarcomas: their value as prognostic indicators.

Authors:  F K Niggli; J E Powell; S E Parkes; K Ward; F Raafat; J R Mann; M C Stevens
Journal:  Br J Cancer       Date:  1994-06       Impact factor: 7.640

4.  Cellular kinetics in rectal cancer.

Authors:  N H Terry; M L Meistrich; L D Roubein; P M Lynch; R A Dubrow; T A Rich
Journal:  Br J Cancer       Date:  1995-08       Impact factor: 7.640
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.